Research Topics
| R MainiSummaryAffiliation: Imperial College Country: UK Publications
| Collaborators
|
Detail Information
Publications
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupR Maini
The Kennedy Institute of Rheumatology and The Imperial College School of Medicine at Charing Cross Hospital, London, UK
Lancet 354:1932-9. 1999..We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate...- Anti-cytokine therapy for rheumatoid arthritisR N Maini
Kennedy Institute of Rheumatology, London, UK
Annu Rev Med 51:207-29. 2000..One anti-TNF reagent has already been approved in the United States for the treatment of RA, and other cytokine antagonists or agonists are under development... 
How does infliximab work in rheumatoid arthritis?Ravinder N Maini
The Kennedy Institute of Rheumatology Division, Imperial College of Science Technology and Medicine, London, UK
Arthritis Res 4:S22-8. 2002....- Current and new antitumor necrosis factor agents in perspectiveRavinder N Maini
Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
Arthritis Res Ther 6:S1-2. 2004 - Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trialE William St Clair
Duke University Medical Center, Durham, North Carolina, USA
Arthritis Rheum 50:3432-43. 2004..CONCLUSION: For patients with active RA in its early stages, combination therapy with MTX and infliximab provides greater clinical, radiographic, and functional benefits than treatment with MTX alone... - Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trialJosef S Smolen
Medical University of Vienna and Lainz Hospital, Vienna, Austria
Arthritis Rheum 54:702-10. 2006.... - Infliximab treatment maintains employability in patients with early rheumatoid arthritisJosef S Smolen
Medical University of Vienna and Lainz Hospital, Vienna, Austria
Arthritis Rheum 54:716-22. 2006..However, patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were treated with MTX alone... - Interleukin-6: a new therapeutic targetJosef S Smolen
Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Arthritis Res Ther 8:S5. 2006..Here, we review recent phase II trials of tocilizumab, a humanized anti-IL-6 receptor antibody that achieves a significant therapeutic response rate... - The pitfalls in the development of biologic therapyRavinder N Maini
Nat Clin Pract Rheumatol 3:1. 2007 - The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritisMarc Feldmann
Kennedy Institute of Rheumatology Division, Imperial College, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
Best Pract Res Clin Rheumatol 18:59-80. 2004..The development of anti-TNF therapy is a key step forward in rheumatology as it is the first new therapy for based on investigating the molecular mechanisms of this disease. This chapter reviews how this discovery was made... - Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?Marc Feldmann
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, London W6 8LH, UK
Novartis Found Symp 256:53-69; discussion 69-73, 106-11, 266-9. 2004..The era of anti-cytokine therapeutics is just dawning... - Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseasesMarc Feldmann
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, 1 Aspenlea Road, London W6 8LH, UK
Nat Med 9:1245-50. 2003 - Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by BoersPeter E Lipsky
Arthritis Rheum 46:2817-8; author reply 2718-21. 2002 - Cytokines and anti-cytokine biologicals in autoimmunity: present and futureEvangelos T Andreakos
Faculty of Medicine, Kennedy Institute of Rheumatology Division, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
Cytokine Growth Factor Rev 13:299-313. 2002..The future developments of anti-TNFalpha and anti-cytokine therapy in general will be interesting... - Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studiesMarc Feldmann
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, London, UK
Joint Bone Spine 69:12-8. 2002..There is now extensive clinical use of anti-TNFalpha biologicals for severe rheumatoid arthritis in the US and Europe... 
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alphaMichael J Elliot
Clinical Immunology Division, Kennedy Institute of Rheumatology, London W6 7DW, United Kingdom
Arthritis Rheum 58:S92-S101. 2008..To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA)...- Gene studies, anti-TNF therapy take Lasker honorsMike Mitka
JAMA 290:1979-80. 2003 - A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody contentEng M Tan
Autoantibody Standardization Committee in Rheumatic and Related Disorders of the International Union of Immunological Societies, The World Health Organization, The Arthritis Foundation, and Centers for Disease Control and Prevention
J Rheumatol 29:68-74. 2002..Improved EIA kits would lend themselves to reliable quantitation of antibody levels in human sera and help to determine whether serial measurement of antibody levels might be useful in monitoring disease activity...